BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 21105995)

  • 1. High-dose cefazolin on consecutive hemodialysis in anuric patients with Staphylococcal bacteremia.
    Renaud CJ; Lin X; Subramanian S; Fisher DA
    Hemodial Int; 2011 Jan; 15(1):63-8. PubMed ID: 21105995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia.
    Stryjewski ME; Szczech LA; Benjamin DK; Inrig JK; Kanafani ZA; Engemann JJ; Chu VH; Joyce MJ; Reller LB; Corey GR; Fowler VG
    Clin Infect Dis; 2007 Jan; 44(2):190-6. PubMed ID: 17173215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness of cefazolin versus cloxacillin as definitive antibiotic therapy for MSSA bacteraemia: results from a large multicentre cohort study.
    Bai AD; Showler A; Burry L; Steinberg M; Ricciuto DR; Fernandes T; Chiu A; Raybardhan S; Science M; Fernando E; Tomlinson G; Bell CM; Morris AM
    J Antimicrob Chemother; 2015 May; 70(5):1539-46. PubMed ID: 25614044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daptomycin versus placebo as an adjunct to beta-lactam therapy in the treatment of Staphylococcus aureus bacteremia: study protocol for a randomized controlled trial.
    Cheng MP; Lawandi A; Butler-Laporte G; Paquette K; Lee TC
    Trials; 2018 May; 19(1):297. PubMed ID: 29843781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of outcomes in patients with methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia who are treated with β-lactam vs vancomycin empiric therapy: a retrospective cohort study.
    Wong D; Wong T; Romney M; Leung V
    BMC Infect Dis; 2016 May; 16():224. PubMed ID: 27215201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia.
    Schweizer ML; Furuno JP; Harris AD; Johnson JK; Shardell MD; McGregor JC; Thom KA; Cosgrove SE; Sakoulas G; Perencevich EN
    BMC Infect Dis; 2011 Oct; 11():279. PubMed ID: 22011388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of cloxacillin versus cefazolin for methicillin-susceptible
    Burdet C; Loubet P; Le Moing V; Vindrios W; Esposito-Farèse M; Linard M; Ferry T; Massias L; Tattevin P; Wolff M; Vandenesch F; Grall N; Quintin C; Mentré F; Duval X; Lescure FX;
    BMJ Open; 2018 Sep; 8(8):e023151. PubMed ID: 30173161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. β-Lactam Therapy for Methicillin-Susceptible Staphylococcus aureus Bacteremia: A Comparative Review of Cefazolin versus Antistaphylococcal Penicillins.
    Li J; Echevarria KL; Traugott KA
    Pharmacotherapy; 2017 Mar; 37(3):346-360. PubMed ID: 28035690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of safety and outcomes with cefazolin versus nafcillin for methicillin-susceptible Staphylococcus aureus bloodstream infections.
    Miller MA; Fish DN; Barber GR; Barron MA; Goolsby TA; Moine P; Mueller SW
    J Microbiol Immunol Infect; 2020 Apr; 53(2):321-327. PubMed ID: 30190234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cefazolin versus cloxacillin as definitive antibiotic therapy for methicillin-susceptible Staphylococcus aureus spinal epidural abscess: a retrospective cohort study.
    Bai AD; Findlater A; Irfan N; Singhal N; Loeb M
    Int J Antimicrob Agents; 2021 Nov; 58(5):106429. PubMed ID: 34469802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implementation of a cefazolin-based stewardship pathway for methicillin-susceptible Staphylococcus aureus bloodstream infections paired with infectious diseases consultation.
    Lee BJ; Rao SN; Wang SK; Lee JY; Lakada IY; Gilbert EM; Barr VO; Postelnick MJ; Sutton SH; Zembower TR; Bolon M; Scheetz MH; Rhodes NJ
    Int J Antimicrob Agents; 2017 May; 49(5):650-654. PubMed ID: 28279787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contemporary use of cefazolin for MSSA infective endocarditis: analysis of a national prospective cohort.
    Herrera-Hidalgo L; Muñoz P; Álvarez-Uría A; Alonso-Menchén D; Luque-Marquez R; Gutiérrez-Carretero E; Fariñas MDC; Miró JM; Goenaga MA; López-Cortés LE; Angulo-Lara B; Boix-Palop L; de Alarcón A;
    Int J Infect Dis; 2023 Dec; 137():134-143. PubMed ID: 37926195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and outcomes of antimicrobial treatment for Staphylococcus aureus bacteremia in outpatients with ESRD.
    Chan KE; Warren HS; Thadhani RI; Steele DJ; Hymes JL; Maddux FW; Hakim RM
    J Am Soc Nephrol; 2012 Sep; 23(9):1551-9. PubMed ID: 22904350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A large retrospective cohort study of cefazolin compared with flucloxacillin for methicillin-susceptible Staphylococcus aureus bacteraemia.
    Davis JS; Turnidge J; Tong S
    Int J Antimicrob Agents; 2018 Aug; 52(2):297-300. PubMed ID: 29499317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cefazolin versus anti-staphylococcal penicillins for treatment of methicillin-susceptible Staphylococcus aureus bacteraemia: a narrative review.
    Loubet P; Burdet C; Vindrios W; Grall N; Wolff M; Yazdanpanah Y; Andremont A; Duval X; Lescure FX
    Clin Microbiol Infect; 2018 Feb; 24(2):125-132. PubMed ID: 28698037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical implications of cefazolin inoculum effect and β-lactamase type on methicillin-susceptible Staphylococcus aureus bacteremia.
    Lee S; Kwon KT; Kim HI; Chang HH; Lee JM; Choe PG; Park WB; Kim NJ; Oh MD; Song DY; Kim SW
    Microb Drug Resist; 2014 Dec; 20(6):568-74. PubMed ID: 25000230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Empirical use of β-lactam/β-lactamase inhibitor combinations does not increase mortality compared with cloxacillin and cefazolin in methicillin-susceptible Staphylococcus aureus bacteraemia: a propensity-weighted cohort study.
    Willekens R; Puig-Asensio M; Suanzes P; Fernández-Hidalgo N; Larrosa MN; González-López JJ; Rodríguez-Pardo D; Pigrau C; Almirante B
    J Antimicrob Chemother; 2022 Jul; 77(8):2288-2295. PubMed ID: 35552420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness of β-lactam versus vancomycin empiric therapy in patients with methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia.
    Wong D; Wong T; Romney M; Leung V
    Ann Clin Microbiol Antimicrob; 2016 Apr; 15():27. PubMed ID: 27112143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Nafcillin and Cefazolin for the Treatment of Methicillin-Susceptible Staphylococcus aureus Bacteremia.
    Twilla JD; Algrim A; Adams EH; Samarin M; Cummings C; Finch CK
    Am J Med Sci; 2020 Jul; 360(1):35-41. PubMed ID: 32376001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nafcillin versus cefazolin for the treatment of methicillin-susceptible Staphylococcus aureus bacteremia.
    Monogue ML; Ortwine JK; Wei W; Eljaaly K; Bhavan KP
    J Infect Public Health; 2018; 11(5):727-731. PubMed ID: 29526442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.